BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/14/2025 10:52:07 AM | Browse: 45 | Download: 133
 |
Received |
|
2025-04-07 09:40 |
|
Peer-Review Started |
|
2025-04-16 09:01 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-04-24 02:46 |
|
Revised |
|
2025-05-08 15:16 |
|
Second Decision |
|
2025-06-17 02:48 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-07-02 09:11 |
|
Articles in Press |
|
2025-07-02 09:11 |
|
Publication Fee Transferred |
|
2025-05-10 16:23 |
|
Edit the Manuscript by Language Editor |
|
2025-07-17 21:04 |
|
Typeset the Manuscript |
|
2025-08-04 02:59 |
|
Publish the Manuscript Online |
|
2025-08-14 10:52 |
| ISSN |
1948-9358 (online) |
| Open Access |
Diabetic cystopathy (DCP), a debilitating complication of diabetes mellitus, involves hyperglycemia-driven bladder dysfunction. This study identified CREB3 L3 as a novel mediator of DCP pathogenesis. Chronic hyperglycemia induced CREB3 L3 overexpression in bladder urothelium, promoting C-reactive protein-dependent inflammation, epithelial-mesenchymal transition (EMT) and tight junction disruption. Silencing CREB3 L3 in SV-HUC-1 urothelial cells and a DCP rat model reversed EMT markers (downregulation of N-cadherin and upregulation of E-cadherin protein), restored barrier proteins (Occludin/Claudin1 protein), and attenuated bladder remodeling. These findings have established CREB3 L3 as a therapeutic target to preserve urothelial integrity and mitigate DCP progression. |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Urology & Nephrology |
| Manuscript Type |
Basic Study |
| Article Title |
Hyperglycemia-induced overexpression of CREB3 L3 promotes the epithelial-to-mesenchymal transition in bladder urothelial cells in diabetes mellitus
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Qing-Guo Wu, Ming-Jin Zhang, Yi-Bi Lan, Chun-Lei Ma and Wei-Jin Fu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| GuangXi Natural Science Foundation |
2024GXNSFAA010031 |
|
| Corresponding Author |
Wei-Jin Fu, Chief Physician, Department of Urology, The First Affiliated Hospital of GuangXi Medical University, No. 6 Shuangyong Road, Qinxiu District, Nanning 530022, Guangxi Zhuang Autonomous Region, China. fwjgxmu1978@163.com |
| Key Words |
Hyperglycemia; Epithelial-mesenchymal transition; Diabetic cystopathy |
| Core Tip |
Diabetic cystopathy (DCP), a debilitating complication of diabetes mellitus, involves hyperglycemia-driven bladder dysfunction. This study identified CREB3 L3 as a novel mediator of DCP pathogenesis. Chronic hyperglycemia induced CREB3 L3 overexpression in bladder urothelium, promoting C-reactive protein-dependent inflammation, epithelial-mesenchymal transition (EMT) and tight junction disruption. Silencing CREB3 L3 in SV-HUC-1 urothelial cells and a DCP rat model reversed EMT markers (downregulation of N-cadherin and upregulation of E-cadherin protein), restored barrier proteins (Occludin/Claudin1 protein), and attenuated bladder remodeling. These findings have established CREB3 L3 as a therapeutic target to preserve urothelial integrity and mitigate DCP progression. |
| Publish Date |
2025-08-14 10:52 |
| Citation |
<p>Wu QG, Zhang MJ, Lan YB, Ma CL, Fu WJ. Hyperglycemia-induced overexpression of CREB3 L3 promotes the epithelial-to-mesenchymal transition in bladder urothelial cells in diabetes mellitus. <i>World J Diabetes</i> 2025; 16(8): 108101</p> |
| URL |
https://www.wjgnet.com/1948-9358/full/v16/i8/108101.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v16.i8.108101 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
